Palatin Technologies (PTN) Fundamentals 2026 — Revenue Analysis | SniperIQ
Palatin Technologies (PTN) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Palatin Technologies's market cap?
Palatin Technologies (PTN) has a market capitalization of approximately
What is Palatin Technologies's P/E ratio?
Palatin Technologies's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Palatin Technologies?
Palatin Technologies runs a net profit margin of -48.5%, a gross margin of 99.8%, and an operating margin of -50.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Palatin Technologies pay a dividend?
Palatin Technologies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Palatin Technologies financially healthy?
Palatin Technologies carries a debt-to-equity ratio of 0.03x and a current ratio of 5.04x, with a market beta of -0.07. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Palatin Technologies a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Palatin Technologies (PTN) the key facts are: market cap
Track Palatin Technologies's full fundamentals live
Get Palatin Technologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.